insitro vs Isomorphic Labs (2026)
The most celebrated lineage in computational biology against a company that publishes its method. Isomorphic descends from the structure prediction work that changed the field and offers a unified design engine spanning structure, binding, affinity and antibody modelling, with named pharmaceutical collaborations. insitro generates its own cellular data through stem cell models, genome editing and high content imaging, submitted its core method to peer review, and tests model hypotheses experimentally before they advance. The asymmetry is stage rather than quality: Isomorphic has no software to license, no published method behind the commercial engine and no molecule in a human yet. Pedigree is public and a platform is not, and a partner should not accept one as evidence of the other.
- It generates its own multimodal cellular data through stem cell models, genome editing and high content imaging, so the platform produces the biology it learns from.
- The core method was submitted to peer review rather than described in marketing, and model hypotheses are tested experimentally before advancing.
- Capital position is disclosed with precision, which matters when choosing a partner for a decade long programme.
- The lineage is the strongest in structure prediction and the engine unifies structure, ligand binding, affinity and antibody modelling in one system.
- Named multi target discovery collaborations tell a partner what working with the company actually involves.
- Designs enter a pharmaceutical partner's own development process, so oversight is structurally the partner's.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. insitro and Isomorphic Labs are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | insitro | Isomorphic Labs |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2018 | 2021 |
| Headquarters | South San Francisco, CA | London, United Kingdom |
| Website | insitro.com | isomorphiclabs.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards insitro its top capability grade on AI Centrality and Model and Technology Transparency. Set against Isomorphic Labs, insitro grades higher on several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and Clinical and Operational Evidence. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Isomorphic Labs its top capability grade on AI Centrality. Set against insitro, Isomorphic Labs grades higher on Setting and Specialty Coverage. Its thinnest published disclosure sits on AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose insitro or Isomorphic Labs?
On the axes where the AI Health Index separates them, insitro grades higher on several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and Clinical and Operational Evidence, and Isomorphic Labs grades higher on Setting and Specialty Coverage. insitro leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do insitro and Isomorphic Labs differ most?
The widest separation the AI Health Index records between insitro and Isomorphic Labs is on Model and Technology Transparency, where insitro grades A and Isomorphic Labs grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do insitro and Isomorphic Labs grade the same?
The AI Health Index grades insitro and Isomorphic Labs the same on several axes, including AI Centrality, Autonomy and Oversight Model and AI Safety and PHI Stewardship. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have insitro and Isomorphic Labs not disclosed?
At the last review, at least one of insitro and Isomorphic Labs published thin or absent detail on AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
The disclosure asymmetry is the substance here: one publishes its method in peer review and generates the data it learns from, while the other has no software to license, no published method behind the commercial engine, no benchmark and no molecule in a human, with first in human work targeted for the end of 2026. That is a statement of stage rather than of quality, and a partner should not accept lineage as a substitute for a platform. Neither holds a located security attestation, and neither publishes cell line or donor provenance.